Post Reply
7881-7900 of 10899
This company and it's breakthrough product alone can sustain it's position for a long time to come...
just like Apple Computers previosuly ...
Bro.Impossible ,Thank you so much.
GREAT NEWS!!!! Price not up !!!!!!!!!!!!
CE mark approve price down!!!!!!!!!!!!!!!!!1
|
柏盛国际总裁陆友纪 (2008-02-17) |
陆友纪从小在日本长大，随后在美国大学读书、工作，并曾在日本和新加坡工作。他在1990年投入450万美元创办?柏盛国际?（Biosensors），主要研制、生产并销售心脏治疗器材。
公司近来把耗资1亿美元、花费七年研发的最新产品??Biomatrix DES药物涂层心血管支架，推向国际市场，让业绩有望转亏为盈。该产品针对亚洲人的人体特征而设计，因为这位总裁怀有深厚的亚洲情意结。
?我对亚洲有着很深厚的感情，无论离开多久，我喜欢吃的仍然是米饭，始终喜欢亚洲的文化，也仍然信仰亚洲的哲学。?
上市公司?柏盛国际?主席兼总裁陆友纪一语道出对亚洲的执著，这也是他当初坚持白手起家，独立创业的原因。
50多岁的陆友纪身为美籍华人，从小在日本长大，随后在美国修读大学、工作，并曾在日本和新加坡工作。他在1990年一手建立了柏盛国际，主要研制、生产并销售心脏治疗器材，而公司最初的产品主要是针对亚洲人的人体特征而设计。
陆友纪说，世上有一半以上的人口集中在亚洲。西医是建立在对西方人临床试验的基础上，转而运用在亚洲病人身上，以为亚洲人与西方人有相同的身体特征。实际上，与欧美人相比，亚洲人的血管等内部构造更为窄小、复杂，所以产品研发的难度也更高。而现在柏盛国际产品的柔韧性和便利，已得到国际知名血管专家的认可。
获CE Mark认证
点亮进军国际市场绿灯
此外，公司耗资近1亿美元（约1.41亿新元）的Biosensors经过七年的研发后，日前获得了CE Mark的认证。陆友纪说，这一认证为公司打开了通向欧盟、亚洲以及拉丁美洲等受认可市场的大门，公司预计在08财年可取得最少1亿美元的营收，在下半年达到保本甚至转亏为盈，赢利也将每季度递增。
陆友纪有感而发：?我们要成为研发和赢利并行的公司，下一步目标就是争取利润、创造成绩并建立信誉。?
Biomatrix DES是由柏盛国际内部开发，利用生物可分解聚合物以及公司的专利药品Biolimus A9进行研制，大大提高此类产品的安全性能和功效。其中，Biolimus A9具有抑制和消炎效用，并能加速人体组织的吸收能力，提高局部药效；而生物可分解聚合物可在药物释放的同时完全分解成水分和二氧化碳，从而使留下的心血管支架具有生物相容性，同时这一材料的使用，也可及时控制药物的释放。
陆友纪表示，目前市场上很多同类型产品的安全功能和耐久性仍有缺陷，这也是他当年起意研究这一新产品的主因。
药物涂层心血管支架
计划4月1日全面上市
CE Mark的认证，为公司点亮了绿灯，把这一技术推向市场。他说，药物涂层心血管支架市场的潜力无限，在日本除外的亚洲市场，市场总值达8亿美元（12亿新元），公司希望三年内取得25％的市场占有率。
公司已计划4月1日将该产品全面推出市场，通过分销渠道在新加坡、印尼、马来西亚、泰国、菲律宾，以及德国、意大利、西班牙和瑞士等地率先推出，随后逐渐扩大范围，提高营业额。陆友纪透露，由于相关条例，公司争取半年后进入印度市场，一年内把产品打入台湾、韩国、澳洲等市场。
他说，随着世界各地条规要求越来越复杂，向市场引进新技术难度也逐渐增大，公司获得这一认证的时机可谓恰到好处。凭借CE Mark认证，公司可直接进入的市场总值达12亿，一年后业务可伸展到的市场总值是20亿。而在本地，公司的Biomatrix DES已陆续推出市场，也与一些医院及心脏专科院所接洽，寻求合作机会。
新产品拟引入中国市场
公司计划一年半内能顺利把产品引入中国市场。
公司在去年9月以1000万美元现金外加1亿2900万新股的价格，收购山东吉威医疗制品有限公司（JW Medical Systems Ltd）的50％股权。
之后，公司又在年初与香港上市公司山东威高集团医用高分子制品股份有限公司达成协议，收购吉威的30％股权，并给予对方在明年7月30日前脱售剩余20％股权的选择权。
2006年成立的吉威是中国药物涂层血管支架供应商，拥有约25％的市场占有率。
陆友纪说，公司将利用这一优势推出Biomatrix DES，进而拓展中国市场，相信很快就可以成为同业的领头羊。
欧日市场不可忽略
尽管公司的优势主要在亚洲，但庞大的欧洲市场仍不能忽略。目前，欧洲市场价值已超过10亿美元。陆友纪说，公司目前在欧洲的分销网络不像亚洲那样广泛和深入，拓展速度也不如亚洲快，公司的目标是在三年内能取得10％欧洲市场占有率。
日本也是另一个不可忽视的市场，当地市场总值也达8亿美元。拥有柏盛国际执照的日本医药与器材供应商Terumo公司的NOBORI DES系统也获得了CE Mark的认证，作为可提供、利用这一技术而生产的药物涂层血管支架仅有的两间公司，柏盛国际希望能在未来三年内争取到20％的市场占有率。
他只是半路出山
正如陆友纪所说，研制Biosensors产品的首七年充满血和泪，因为任何一项生命科技上的突破并非朝夕而成。
看总裁如此专业的侃侃而谈，很难想象其实他也只是半路出山，所学的专业与生物无关。他在大学修读机械工程，毕业后进入一家与医药领域相关的公司，30年医学相关工作经验耳濡目染，对人体、动物和医学知识有了一定了解，并在17年前投入450万美元创办公司。
陆友纪本来觉得自己很富有，但成立公司使他一下子变穷了。但?当时还很年轻，靠着对这一行业的热情坚持下来。?
他并不只是把自己的事业当作工作而已，更多的是激情和热忱，希望能够让病人拥有高质量的生活，甚至拯救生命；为心脏病学家提供一项更为便捷的工具；同时也让公司的员工和股东获得不错的收益，从而取得三赢的局面。他说：?我对自己的所作所为非常明确，这也是推动公司成长的动力。?
目前，公司在世界各地设有五家工厂，包括本地两家工厂负责生产产品，在荷兰、日本和中国设有市场销售据点，研发中心则设在美国。公司的全球员工人数有400名，本地员工占多数，约有150名至180名。
在家中讲多种语言
辗转世界各地的生活、学习和工作经历，造就了陆友纪的语言优势。陆友纪的生活和工作并不限于一处，英语与华语之外，他在家里与母亲讲上海话，与妻子讲日语。他从1981年来本地工作，现已是新加坡永久居民，把这里当成第二故乡。
尽管公司的产品正推向世界，但陆友纪表示，亚洲仍是其信仰和热情之所在，而令他感到自豪的是，亚洲正逐渐成为富有活力和吸引力的世界中心。
《联合早报》
（编辑：黄秀茱）
let see today....can break the barrier....87.5
GREAT NEWS!!!!
NEWS RELEASE
FIRST Live Implants of BioMatrix
Mark Approval
® Drug-Eluting Stent in Europe Following CELeading cardiologists implanted six next-generation drug eluting stents in three patients
with complex heart diseases
Rome, 18 February 2008 ?
?Company?, Bloomberg: BIG SP) announced today that its BioMatrix
system was successfully implanted into the first European patients following its Conformité
Européenne (?CE?) Mark approval last month. Two leading cardiologists implanted a total of
six BioMatrix drug-eluting stents in three complex cases that were broadcast live during the
Joint Interventional Meeting 2008 (?JIM?). JIM is a leading meeting of interventional
cardiologists held annually and attended by cardiologists and physicians from around the
world. This scientific meeting, held in Rome, Italy, from 13 ? 15 February, focuses on live
demonstration of interventional procedures.
Professor Eberhard Grube, Chief of Cardiology at the Helios Heart Center in Siegburg,
Germany, and Dr. Gregg W. Stone, Director of Cardiovascular Research and Education at the
New York Presbyterian Hospital-Columbia Medical Center, performed the three procedures
at the Helios Heart Center in Siegburg. The first patient to receive BioMatrix was a 71-yearold
male who is suffering from diabetes and hypertension. He received two BioMatrix drugeluting
stents in a procedure performed by Prof Grube that was broadcast live to the more
than 1,500 attendees on the opening day of JIM.
?The three-year follow-up data released at the Transcatheter Coronary Therapeutics 2007
(?TCT 2007?) demonstrated BioMatrix?s consistent results in terms of safety and clinical
efficacy. This drug-eluting stent has shown excellent procedural performance and outcome
characteristics,? commented Professor Grube.
Prof. Grube also implanted a BioMatrix in a 56-year-old male patient to treat an artery that
became blocked due to restenosis, or re-narrowing, after being previously implanted with a
first-generation drug-eluting stent that utilizes durable polymer as a drug delivery
mechanism. Dr Stone implanted three BioMatrix stents in a third patient, a 57-year-old
male suffering from a totally blocked left anterior descending artery (LAD) and a partially
blocked right coronary artery (RCA). Despite the complicated patient conditions, the two
cardiologists implanted all six BioMatrix drug-eluting stents with 100% procedural success.
?The initial results from these implants are encouraging, and I am very optimistic about the
outcome for these patients, based on the consistently positive clinical trial results achieved
for BioMatrix. This drug-eluting stent system has an excellent deliverability and is especially
useful in treating patients with challenging medical conditions such as the three cases
presented at JIM. I am confident that BioMatrix can become a drug-eluting stent of choice
among cardiologists after it is fully commercialized,? added Professor Grube, who was
responsible for all three live transmissions from Siegburg.
BioMatrix, which received European regulatory approval in January 2008, is a unique drugeluting
stent system that combines a biodegradable polymer and the company?s proprietary
anti-restenotic drug, Biolimus A9
from April 2008.
?These first live implants since BioMatrix received the European regulatory approval are a
very significant milestone for Biosensors,? said Jeffrey B. Jump, Managing Director of
Biosensors Europe SA. ?We are confident that these will be the first of many thousands, as
physicians recognize the long-term benefits of our biodegradable drug delivery system over
earlier generations of drug-eluting stents.?
Biosensors International Group Ltd. (?Biosensors? or the® drug-eluting stent®. The company plans a full European and Asian launch### END OF RELEASE ###
Media Relations & Investor Relations
Biosensors International Group
Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 6213 5708
Email: cm.loh@biosensors.com
Media Relations / Investor Relations Firm
United States
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email:
matt@allencaron.comAbout Biosensors International Group, Ltd
Biosensors develops, manufactures and markets innovative medical devices used in
interventional cardiology and critical care procedures. Biosensors is well-positioned to
emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation
products that are set to gain market share from traditional therapies such as conventional
drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate drugeluting
stent programs,
drug-eluting stent.
For more information, please visit
BioMatrix®, Axxion?, and BioFreedom?, a completely polymer-freewww.biosensors.com.About BioMatrix
®BioMatrix
A9
designed for enhanced deliverability.
Biolimus A9 was designed specifically for use in drug-eluting stent systems. In addition to
effective immunosuppressive and anti-inflammatory properties, the drug has a higher
lipophilic and hydrophobic profile than other limus analogs, enabling rapid absorption of the
drug into the targeted tissue and reduced systemic exposure. Precision automated coating
ensures the PLA and drug combination is applied only to the abluminal (outer) surface of the
stent. The PLA fully degrades into water and carbon dioxide as the drug elutes, ultimately
leaving in place a biocompatible stent surface.
Biosensors will initiate several post marketing surveillance registries on the BioMatrix stent
in April collecting data on over 5000 patients with five year follow-up.
For more information, please visit
® offers the unique combination of an innovative anti-restenotic drug, Biolimus®, a biodegradable poly-lactic acid polymer (PLA), and an advanced, highly flexible stentwww.biomatrix.comForward-Looking Statements
Certain statements herein include forward-looking statements within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally
can be identified by the use of forward-looking terminology, such as ?may,? ?will,? ?expect,?
?intend,? ?estimate,? ?anticipate,? ?believe,? ?project? or ?continue? or the negative thereof
or other similar words. All forward looking statements involve risks and uncertainties,
including, but not limited to, customer acceptance and market share gains, competition from
companies that have greater financial resources; introduction of new products into the
marketplace by competitors; successful product development; dependence on significant
customers; the ability to recruit and retain quality employees as Biosensors grows; and
economic and political conditions globally. Actual results may differ materially from those
discussed in, or implied by, the forward-looking statements. The forward-looking statements
speak only as of the date of this release and Biosensors assumes no duty to update them to
reflect new, changing or unanticipated events or circumstances.
Novena, don't be sad. Still up a credible 2 cents today. Let's BIG move up slowly and steadily and have a closer spread of pricing first. This will help to deter the shortists. Let the sudden surge comes when there are more sustainable grounds, i.e., strong market sentiments, and more importantly LYC is ready to announce the takeover following a period of strong rumour !
ps: Since 'post-CE crash', BIG has recovered quite substantially. Was hovering around 75 cts. Now 86 cts. 11 cents increase without any fresh news. Hopefully more price escalation to come in next few days/weeks to inch close to ANALyst TP of $1.20-$1.30, and then charge ...... to make the right takeover bid a reality !
now 0.86 lor haiz sell too early
As what analyst said BIG will only see profit in mid 2009. I painfully downloaded at leat 100 lots last 21 Dec 07 during Black Mon DJ, making losses, but to no regret. However, I still keep 60 lots for cosolation. Cheers.